Clinical Trial Update: Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating irinotecan hydrochloride liposome in combination with capecitabine as second-line therapy for advanced or metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Carcinoma

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)
• Xeloda (capecitabine)

Snippet

Sponsor: Ba Yi | Conditions: Biliary Tract Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING